Safety of Tocilizumab in COVID-19 Patients and Benefit of Single-Dose: The Largest Retrospective Observational Study

Severe acute respiratory coronavirus-2 (SARS-CoV-2) still presents a public threat and puts extra strain on healthcare facilities. Without an effective antiviral drug, all available treatment options are considered supportive. Tocilizumab as a treatment option has to date shown variable results. In...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Qaaneh, Ayman M., Al-Ghamdi, Fuad H., AbdulAzeez, Sayed, Borgio, J. Francis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8953525/
https://www.ncbi.nlm.nih.gov/pubmed/35335998
http://dx.doi.org/10.3390/pharmaceutics14030624

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8953525/
https://www.ncbi.nlm.nih.gov/pubmed/35335998
http://dx.doi.org/10.3390/pharmaceutics14030624

Ejemplares similares